H. Lundbeck A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 5.6K
- Market Cap
- -
- Website
- http://www.lundbeck.com
Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 44
- Registration Number
- NCT01942733
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 55
- Registration Number
- NCT01942785
- Locations
- 🇺🇸
US015, Tucson, Arizona, United States
🇺🇸US019, Glendale, California, United States
🇺🇸US011, Denver, Colorado, United States
Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01934166
- Locations
- 🇩🇪
DE801, Munich, Germany
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 1986
- Registration Number
- NCT01838681
- Locations
- 🇺🇦
UA007, Kherson,Vil. Stepanivka, Ukraine
🇺🇦UA005, Lviv, Ukraine
🇩🇪DE004, Nuernberg, Germany
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Phase 3
Terminated
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 129
- Registration Number
- NCT01837797
- Locations
- 🇺🇸
US001, National City, California, United States
🇺🇸US008, Orlando, Florida, United States
Brexpiprazole in Patients With Schizophrenia
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 210
- Registration Number
- NCT01810783
- Locations
- 🇺🇸
US004, Kissimmee, Florida, United States
🇺🇸US013, Dallas, Texas, United States
🇺🇦UA009, Lviv, Ukraine
Brexpiprazole in Patients With Acute Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 468
- Registration Number
- NCT01810380
- Locations
- 🇺🇸
US009, Escondido, California, United States
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 295
- Registration Number
- NCT01795547
- Locations
- 🇺🇸
US002, Los Angeles, California, United States
🇺🇸US006, San Diego, California, United States
Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Lu AA21004
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 16
- Registration Number
- NCT01676571
- Locations
- 🇨🇳
CN001, Tianjin, China
Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 12
- Registration Number
- NCT01652313
- Locations
- 🇨🇳
CN001, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath